Under the terms of the agreement, ArcherDX will use their patented Anchored Multiplex PCR technology combined with the Illumina MiSeqDx sequencing system and Archer Analysis bioinformatics software to develop the CDx.
BOULDER, Colo., Nov. 7, 2017 /PRNewswire/ -- ArcherDX announced today that it has signed an agreement to develop and commercialize a next-generation sequencing (NGS)-based oncology companion diagnostic (CDx) for Celgene‘s investigational drug CC-122 for indications in Diffuse Large B Cell Lymphoma (DLBCL).
Under the terms of the agreement, ArcherDX will use their patented Anchored Multiplex PCR (AMP™) technology combined with the Illumina® MiSeqDx™ sequencing system and Archer® Analysis bioinformatics software to develop the CDx. The diagnostic assay is based on a proprietary gene expression signature developed by Celgene to identify DLBCL patients most likely to respond to CC-122, a cereblon-modulating agent currently under investigation in multiple disease settings. ArcherDX will retain the worldwide rights to commercialize the test and will pursue all filings with regional regulatory agencies.
“We look forward to this collaboration arrangement with Celgene to deliver on the promise of precision medicine in a disease indication with high unmet medical need,” Jason Myers, CEO of ArcherDX, said in a statement.
About ArcherDX
ArcherDX addresses the bottlenecks associated with using NGS in oncogenic mutation detection by offering a robust platform for targeted sequencing. By combining proprietary AMP™ chemistry with easy-to-use, lyophilized reagents, Archer NGS assays generate highly enriched sequencing libraries to detect gene fusions, point mutations, CNVs and RNA abundance. Complemented by powerful bioinformatics software, ArcherDX technology dramatically enhances complex mutation identification and discovery.
ArcherDX is headquartered in Boulder, Colorado.
